<html style="font-family:Helvetica,Arial,Sans">
<head><title>Summary Statistics</title><style type = "text/css">
p {
font-size:smaller;
}
table {
border: 0px;
border-collapse:collapse;
font-size:smaller;
table-layout:fixed;
margin-left:0%;
margin-right:auto;
}
.headtab {
width: 100%;
margin-left:auto;
margin-right:auto;
}
th {
background-color: #FFFFFF;
font-weight:bold;
text-align:left;
}
table tr:nth-child(odd) td {
background-color: #FFFFFF;
padding:4px;
word-wrap: break-word;
word-break:break-all;
}
table tr:nth-child(even) td {
background-color: #D3D3D3;
padding:4px;
word-wrap: break-word;
word-break:break-all;
}</style></head><body> <table class="headtab"> <tr><td style="text-align:left">sumtable {vtable}</td> <td style="text-align:right">Summary Statistics</td></tr></table> <h1> Summary Statistics </h1><table><tr><th style = "width:50%; text-align:left">Variable</th><th style = "width:25%; text-align:right">N</th><th style = "width:25%; text-align:right">Percent</th></tr>
| SEXO | 90 | |
| ... Hombre | 81 | 90% |
| ... Mujer | 9 | 10% |
| TABACO | 89 | |
| ... No fumador | 3 | 3% |
| ... Fumador | 41 | 46% |
| ... Ex Fumador | 45 | 51% |
| HTA | 90 | |
| ... no | 37 | 41% |
| ... si | 53 | 59% |
| DIABETES | 90 | |
| ... no | 67 | 74% |
| ... si | 23 | 26% |
| EPOC | 90 | |
| ... no | 43 | 48% |
| ... si | 47 | 52% |
| CARDIOPATIA | 90 | |
| ... no | 63 | 70% |
| ... si | 27 | 30% |
| CLAUDICACION | 90 | |
| ... no | 83 | 92% |
| ... si | 7 | 8% |
| ENFISEMA | 90 | |
| ... no | 45 | 50% |
| ... si | 45 | 50% |
| HISTOLOGIA | 90 | |
| ... ADK | 19 | 21% |
| ... Escamoso | 49 | 54% |
| ... NCLC | 20 | 22% |
| ... Adenoescamoso | 2 | 2% |
| ESTADIAJE | 90 | |
| ... IIB | 7 | 8% |
| ... IIIA | 45 | 50% |
| ... IIIB | 30 | 33% |
| ... IIIC | 7 | 8% |
| ... IVA | 1 | 1% |
| LOCALIZACION | 90 | |
| ... RUL | 29 | 32% |
| ... RIL | 5 | 6% |
| ... LUL | 29 | 32% |
| ... LIL | 4 | 4% |
| ... RH | 12 | 13% |
| ... LH | 8 | 9% |
| ... Mediastino | 3 | 3% |
| INMUNOTERAPIA | 90 | |
| ... No | 54 | 60% |
| ... Durvalumab | 32 | 36% |
| ... Atezolizumab | 2 | 2% |
| ... Nivolumab | 2 | 2% |
| GRADO RTOG NEUMONITIS | 90 | |
| ... G1&G2 | 73 | 81% |
| ... G3&G4 | 17 | 19% |
| LONGITUD TELOMERICA | 90 | |
| ... Percentil<1% | 8 | 9% |
| ... Percentil<10% | 11 | 12% |
| ... Percentil<25% | 15 | 17% |
| ... Percentil 25% | 2 | 2% |
| ... Percentil 25-50% | 33 | 37% |
| ... Percentil 50% | 5 | 6% |
| ... Percentil 50-75% | 10 | 11% |
| ... Percentil>75% | 4 | 4% |
| ... Percentil>90% | 2 | 2% |
| EXITUS | 90 | |
| ... no | 31 | 34% |
| ... si | 59 | 66% |